Xenon Pharmaceuticals Inc. (XENE) stock
XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
$38.78−0.48 (-1.22%)
Close on Nov 17, 2026Market cap $3.76BP/E –Yield –
Xenon Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Xenon Pharmaceuticals's price to sales ratio was 461.2× on Feb 27, 2026, against 261.8× a year earlier. Over the last 5 years it ranged from 12.5× to 461.2×, with a median of 70.1×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Feb 27, 2026 | 461.2× | +0.3 |
| 2025 | Dec 31, 2025 | 460.9× | +193.6 |
| 2023 | Apr 28, 2023 | 267.2× | +80.0 |
| 2022 | Dec 30, 2022 | 187.2× | +122.1 |
| 2021 | Dec 31, 2021 | 65.2× | +47.4 |
| 2020 | Dec 31, 2020 | 17.7× | −335.3 |
| 2018 | Apr 30, 2018 | 353.0× | +277.2 |
| 2017 | Dec 29, 2017 | 75.8× | +46.2 |
| 2016 | Dec 30, 2016 | 29.6× | +22.9 |
| 2015 | Dec 31, 2015 | 6.7× | +5.8 |
| 2014 | Dec 31, 2014 | 0.9× | – |
See a number that looks wrong?